This is a non-randomized, open-label, Phase 1 study of Atezolizumab (MPDL3280A, Anti-PD-L1 antibody) monoclonal antibody [mAb] in intermediate/high/very high-risk myelodysplastic syndromes (MDS) patients, as evaluated by the International Prognostic Scoring System-Revised (IPSS-R). Eligible participants will either have never received treatment with hypomethylating agents(s) (HMAs) or have relapsed or are refractory to prior HMA therapy. The primary objectives of this study are to determine the safety and feasibility of Atezolizumab therapy in these patient populations, including treatment in combination with azacitidine.
Clinical Trial: NCT02508870
A Safety and Pharmacology Study of Atezolizumab (MPDL3280A, Anti-PD-L1 Antibody) Administered Alone or in Combination With Azacitidine in Patients With Myelodysplastic Syndromes